ArticleFrontiers in cardiovascular medicine2026
Serum copeptin predicts atrial fibrillation recurrence and is associated with increased all-cause mortality.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Copeptin, a stable surrogate marker of arginine vasopressin, reflects neurohumoral activation and hemodynamic stress. Its prognostic value in heart failure is established, but its role in atrial fibrillation (AF) recurrence and mortality remains unclear. This study aimed to compare copeptin concentrations in patients with AF and controls, evaluate biochemical and echocardiographic associations, and assess copeptin associations with 12-month AF recurrence and all-cause mortality. Methods: This prospective observational study included 100 hospitalized patients with AF and 50 controls in sinus rhythm. Participants underwent clinical evaluation, echocardiography, biochemical testing, and measurement of copeptin, N-terminal pro-B-type natriuretic peptide (NT-proBNP), and high-sensitivity cardiac troponin T (hsTnT). AF recurrence was evaluated in 62 patients after sinus-rhythm restoration; mortality was assessed in all 100 patients over a 12-month follow-up period. Results: Median copeptin concentration was higher in patients with AF than in controls, 14.52 (6.98-36.83) versus 4.10 (2.70-6.88) pmol/L ( Discussion: In hospitalized patients with AF, copeptin is elevated and associated with cardiac biomarkers, inflammation, and structural and functional echocardiographic abnormalities. Higher copeptin independently predicts AF recurrence after sinus-rhythm restoration and is associated with 12-month all-cause mortality, supporting its potential for risk stratification and prognostic assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.